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Figure 1. Comparison between secukinumab Ctrough in optimal and suboptimal responders and
visualization of a therapeutic window of secukinumab. (a) Correlation between Ctrough and clinical
response; Spearman rank test (r ¼ e0.442; P ¼ 0.004). (b) Ctrough was compared between suboptimal
(PASI > 2; n ¼ 17) and optimal (PASI  2; n ¼ 23) responders. (c) ROC analysis of secukinumab Ctrough.
Optimal cut-off point was selected by using the index of union (Unal, 2017). The minimal effective Ctrough
was set at 33.2 mg/ml. (d) Four equal-sized groups (n ¼ 10) were formed based on ascending Ctrough and
correlated with the median DPASI per group. Each black dot represents the median Ctrough, with
correlating median DPASI for one group. Alongside each DPASI, the IQR is illustrated. The dashed vertical
line represents the minimal effective secukinumab Ctrough of 33.2 mg/ml. AUC, area under the curve;
Ctrough, trough concentration; IQR, interquartile range; PASI, Psoriasis Area and Severity Index; DPASI,
percentage of PASI improvement with baseline; ROC, receiver operating characteristic.TO THE EDITOR
The armamentarium of psoriasis treat-
ments has been reinforced by the
introduction of biologics that target IL-
17A (European Medicines Agency,
2015; Frieder et al., 2018), and at pre-
sent, achieving complete skin clear-
ance has become a realistic goal.
However, in clinical practice, physi-
cians encounter various levels of re-
sponses, including insufficient response
or loss of response with antieIL-17A
treatment. This has led to physicians
exploring off-label intensification reg-
imens through trial and error, either
by increasing the dose or by short-
ening the administration intervals
(Beecker and Joo, 2018; Phung et al.,
2018). Thus, there is a current need to
target the most optimal therapeutic
response in an individual patient
to use these highly effective and
expensive drugs in a manner as cost-
effective as possible. Therapeutic
drug monitoring, in which dose ad-
justments are based on a definable
relationship between measurable
serum drug concentrations, often
taken at trough (Ctrough), and a clinical
observable response can be used to
reach this goal (Toro-Montecinos
et al., 2019; Wilkinson et al., 2019).
Nevertheless, to implement therapeu-
tic drug monitoring, it is crucial to
define the optimal therapeutic win-
dow for a given biologic in psoriasis
(Hoseyni et al., 2018).
In this pilot study, we studied secu-
kinumab, a fully human antieIL-17A
monoclonal antibody, Ctroughs in 40
patients with moderate to severe pso-
riasis, who administered secukinumabAbbreviations: CI, confidence interval; Ctrough, trough
Index
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nc-nd/4.0/).monthly during maintenance, using
an in-houseedeveloped, sandwich-type
enzyme-linked immunosorbent assay.
The medical ethics committee from the
Ghent University Hospital, Belgium,
approved this study (B670201835652),
and written informed consent was ob-
tained from all patients before anyconcentration; PASI, Psoriasis Area and Severity
ed proof published online XXX
ehalf of the Society for Investigative Dermatology.
D license (http://creativecommons.org/licenses/by-study procedure was performed. The
Psoriasis Area and Severity Index
(PASI) was assessed by a dermatologist
before sample collection, and clinical
response was established by comparing
the percentage of PASI improvement
with baseline (DPASI). Patients were
classified as optimal responders (PASI
 2) or suboptimal responders (PASI >
2), as an absolute PASI cut-off of 2 is
associated with the DPASI 90 response
(Reich et al., 2018).
In our patient cohort (see
Supplementary Table S1 online), we
found a significant correlation betweenwww.jidonline.org 1
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Figure 2. Proposed monitoring algorithm for patients with psoriasis treated with secukinumab during maintenance phase. Before measuring Ctrough, patient’s
adherence needs to be checked. If correct, the combination of clinical evaluation (PASI) and the minimal effective Ctrough provide an algorithm to adequately
monitor patients with psoriasis treated with secukinumab during maintenance phase (minimal 24 weeks). (a, b) In optimal responders, secukinumab treatment
can be continued, but it is recommended to check Ctrough when loss of response occurs. (c) In suboptimal responders with subtherapeutic Ctrough, a dose
escalation is recommended. (d) In suboptimal responders with therapeutic Ctrough, it is recommended to switch to another biologic. The dashed horizontal and
vertical line represent the absolute PASI 2 and Ctrough threshold level (33.2 mg/ml), respectively. Ctrough, trough concentration; PASI, Psoriasis Area and
Severity Index; TDM, therapeutic drug monitoring.
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2secukinumab Ctrough and absolute PASI
(r ¼ e0.442; P ¼ 0.004; Figure 1a) as
well as between Ctrough and relative
DPASI (r ¼ 0.325; P ¼ 0.041). In
addition, a significant difference in
Ctrough was observed between optimal
responders and suboptimal responders
(P ¼ 0.004; Figure 1b), with a median
Ctrough of 40.2 mg/ml and 29.1 mg/ml,
respectively. This correlation suggests a
therapeutic window of secukinumab in
patients with psoriasis.
Next, we sought the minimal
effective threshold of the therapeutic
window by using a receiver operator
characteristic analysis and found a
minimal effective maintenance secu-
kinumab Ctrough of 33.2 mg/ml with an
area under the curve of 0.76 (95%
confidence interval [CI] ¼ 0.61e0.92;
P ¼ 0.005), sensitivity 78.3% (95%
CI ¼ 56.3e92.5), and specificity
76.5% (95% CI ¼ 50.1e93.2), which
was associated with a positive and
negative predictive value of 0.82
(95% CI ¼ 0.59e0.94) and 0.72
(95% CI ¼ 0.46e0.89), respectively
(Figure 1c) (Unal, 2017). This Ctrough
indicative of the minimal desirable
effect implies that a secukinumab
Ctrough of 33.2 mg/ml can distinguish
optimal responders (PASI  2) from
suboptimal responders (PASI > 2).
In addition, we created a
concentration-effect curve to elucidate
whether the Ctrough, indicating the
maximum clinical effect, could be
determined. Although relative DPASI
increased with increasing secukinumabJournal of Investigative Dermatology (2019), VolumCtrough, no plateau was observed, and
thus, no upper Ctrough threshold could
be deduced in this cohort (Figure 1d).
To explore potential confounding
factors of Ctrough and/or clinical
response, several correlations were
tested. These results showed that
obesity, active smoking, long treatment
duration, and/or previous treatment
with biologics were associated with
lower secukinumab Ctrough, which also
resulted in lower clinical responses.
A limitation of our study is the small
sample size that hampers a multivar-
iate analysis. In addition, using the
receiver operator characteristic anal-
ysis, the discrimination between
optimal and suboptimal responders
was only fair and may not be useful for
clinical practice. Therefore, these
findings need to be confirmed in a
larger cohort as it is not unlikely that
some patients may have an increased
clearance of therapeutic antibodies or
IgG in general.
Based on these results, we propose a
treatment algorithm by combining
clinical evaluation (PASI) and the min-
imal effective Ctrough to adequately
monitor patients with psoriasis who are
treated with secukinumab during the
maintenance phase (Figure 2).
This algorithm highlights the potential
added value of Ctrough measurement in
the clinic because it enables the
physicians to make guided decisions
instead of the current trial-and-error
dose adaptations. In suboptimal re-
sponders with subtherapeutic Ctrough,e -we suggest a dose escalation, which
will inevitably lead to an increased
cost. Nevertheless, measuring the
secukinumab Ctrough allows to select a
priori those suboptimal responders in
whom it is justified to dose escalate,
defining an appropriate extra cost.
In summary and to our knowledge
previously unreported, we describe a
minimal effective secukinumab Ctrough
of 33.2 mg/ml and consequently unveil
a potential role of therapeutic drug
monitoring in patients with psoriasis
who are treated with secukinumab.
Our results suggest that patients with
psoriasis with a suboptimal response
and a Ctrough below 33.2 mg/ml during
the maintenance phase are potentially
undertreated and could benefit from
dose intensification.Data Availability Statement
The data set related to this article can
be found at https://osf.io/sbxpj/, hosted
at Open Science Framework, and ac-
cess can be obtained upon request.
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Supplementary Table S1. Baseline Characteristics of Patients with
Psoriasis Treated with Secukinumab
Characteristic Total Patients (n [ 40)
Age, y, median (IQR) 46.5 (36.3e53.0)
Male sex, n (%) 27 (67.5)
BMI, kg/m2 (mean  SD) 27.9  3.8
Normal (<25), n (%) 8 (20.0)
Overweight (25e30), n (%) 21(52.5)
Obese (30), n (%) 11 (27.5)
Smoking, n (%)
Current smoker 9 (22.5)
PsA, n (%) 6 (15.0)
Disease duration, y, median (IQR) 19.0 (12.0e31.0)
Treatment duration, wk, median (IQR) 55.9 (45.0e103.7)
PASI score before secukinumab treatment, median (IQR) 12.4 (10.3e18.5)
PASI score at trough, median (IQR) 1.4 (0.0e3.6)
Secukinumab Ctrough, mg/ml, median (IQR) 34.6 (28.2e43.0)
Concomitant medication, n (%)
No co-medication 23 (57.5)
Topical corticosteroids 15 (37.5)
Methotrexate 1 (2.5)
Methotrexate and topical corticosteroids 1 (2.5)
Previous biologic treatment, n (%) 21 (52.5)
Adalimumab 10 (25.0)
Ustekinumab 12 (30.0)
Etanercept 7 (17.5)
Ixekizumab 1 (2.5)
Brodalumab 2 (5.0)
Abbreviations: BMI, body mass index; Ctrough, secukinumab serum trough concentration; IQR,
interquartile range; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; SD, standard
deviation; wk, week; y, year.
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